Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors
Qiuqiang Chen, Lingeng Lu, Wenxue Ma
Cancers (2022) Vol. 14, Iss. 23, pp. 5983-5983
Open Access | Times Cited: 21

Showing 21 citing articles:

The next frontier in immunotherapy: potential and challenges of CAR-macrophages
Jing Li, Ping Chen, Wenxue Ma
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 12
CAR T Cells in Lung Cancer: Targeting Tumor-Associated Antigens to Revolutionize Immunotherapy
Sattam Khulaif Alenezi
Pathology - Research and Practice (2025), pp. 155947-155947
Closed Access | Times Cited: 1
Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance
Liqin Yao, Qingqing Wang, Wenxue Ma
Cancers (2023) Vol. 15, Iss. 24, pp. 5857-5857
Open Access | Times Cited: 14
Understanding the role of endothelial cells in brain tumor formation and metastasis: a proposition to be explored for better therapy
Tejas Girish Agnihotri, Sagar Salave, Tanuja Shinde, et al.
Journal of the National Cancer Center (2023) Vol. 3, Iss. 3, pp. 222-235
Open Access | Times Cited: 10
T-regulatory cells for the treatment of autoimmune diseases
Marina Fisher, С. В. Сенников
Frontiers in Immunology (2025) Vol. 16
Open Access
The Persistent Power of the Taxane/Platin Chemotherapy
Lucy B. Xu, Elizabeth R. Smith, Vasili Koutouratsas, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1208-1208
Open Access
Engineering sonogenetic EchoBack-CAR T cells
Longwei Liu, Peixiang He, Yuxuan Wang, et al.
Cell (2025)
Closed Access
Choosing T-cell sources determines CAR-T cell activity in neuroblastoma
Lorena García‐García, Elena G. Sánchez, M. Ivanova, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Optogenetically engineered Septin-7 enhances immune cell infiltration of tumor spheroids
Jiaxing Chen, Brianna Hnath, Congzhou M. Sha, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 44
Closed Access | Times Cited: 2
Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies
Yangjie Liu, Peng Cao, Faiza Ahad, et al.
Recent Patents on Anti-Cancer Drug Discovery (2024) Vol. 19, Iss. 5, pp. 557-572
Closed Access | Times Cited: 1
Harnessing cytokines to optimize chimeric antigen receptor-T cell therapy for gastric cancer: Current advances and innovative strategies
Zewei Cheng, Xiaohan Cui, Song Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117229-117229
Open Access | Times Cited: 1
Advancing the next generation of cancer treatment with circular RNAs in CAR-T cell therapy
Sanxiong Huang, Juling Xu, Natalia Baran, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 181, pp. 117753-117753
Open Access | Times Cited: 1
TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors
Alaa Alsalloum, Saleh Alrhmoun, Julia Shevchenko, et al.
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2805-2805
Open Access | Times Cited: 3
Inflammatory abrasion of hematopoietic stem cells: a candidate clue for the post-CAR-T hematotoxicity?
Ting Sun, Dengju Li, Liang Huang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 2
Prostate-Specific Membrane Antigen Use in Glioma Management
Joshua D. McBriar, Neeva Shafiian, Stephen C. Scharf, et al.
Clinical Nuclear Medicine (2024)
Closed Access
Editorial: Complexity of tumor microenvironment: A major culprit in cancer development, volume II
Ihtisham Bukhari, Yuanwei Zhang, Rick F. Thorne, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 1
Navigating the Immune Maze: Pioneering Strategies for Un-shackling Cancer Immunotherapy Resistance
Liqin Yao, Qingqing Wang, Wenxue Ma
(2023)
Open Access | Times Cited: 1
Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy
M. Hassaan Rehman, Ariba Qaiser, Hassan Sardar Khan, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access
CAR-T Cell Therapy: Revolutionizing Cancer Treatment
Kirolos Eskandar, Melad Sayh
Indonesian Journal of Cancer Chemoprevention (2024) Vol. 15, Iss. 1, pp. 76-76
Open Access
Therapeutic advances in the targeting of ROR1 in hematological cancers
Adrian Bogdan Țigu, Raluca Munteanu, Cristian Moldovan, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access
Guest Editorial: what can be done to improve cancer immunotherapies?
Hideto Tamura
International Journal of Hematology (2023) Vol. 117, Iss. 5, pp. 631-633
Open Access
Page 1

Scroll to top